摘要
[目的]探讨FBC预处理方案在异基因造血干细胞移植中的可行性。[方法]以FBC预处理对14例恶性血液病患者进行异基因造血干细胞移植。FBC预处理方案组成:磷酸氟达拉滨30mg/(m2·d),静滴,鄄5d～鄄1d;白消安0.6mg/(kg·d),口服,q6h,鄄7d～鄄4d;环磷酰胺30mg/(kg·d),静滴,鄄3d～鄄2d。[结果]14例患者移植后均安全通过骨髓抑制期,顺利重建造血功能,白细胞升至1×109/L为+11d(+9d～+15d),血小板上升至20×109/L为+12d(+9d～+21d)。8例(57.1%)出现急性移植物抗宿主病,5例(35.7%)出现慢性移植物抗宿主病。至今仍存活11例(78.6%),3例(21.4%)死亡。[结论]用FBC预处理方案进行异基因造血干细胞移植治疗恶性血液病安全、有效。
To explore the feasibility of FBC conditioning regimen in allogeneic hematopoietic stem cell transplantation. FBC conditioning regimen consisting of fludarabine 30 mg/(m2·d),-5d～-1d; and Busulfan 0.6 mg/(kg·d),q6h,-7d～-4d; and cyclophosphamide 30 mg/(kg·d),-3d～-2d, was used for allogeneic stem cell transplantation in 14 cases with hematological malignancies. All 14 cases passed the hematological suppression stage smoothly and achieved engraftment of the donor cells. WBC rose to 1×109/L on day +11(+9d～+15d), and Platelets rose to 20×109/L on day +12(+9d～+21d). Eight cases(57.1%) developed acute GVHD and 5 cases(35.7%) chronic GVHD. Eleven cases(78.6%) were still alive and 3 cases(21.4%) died now. [Conclusion] FBC conditioning regimen in allogeneic hematopoietic stem cell transplantation is safe and effective for treatment of hematological malignancies.
出处
《肿瘤学杂志》
CAS
2004年第6期393-394,共2页
Journal of Chinese Oncology
关键词
造血干细胞移植
异基因
恶性血液病
预处理
hematopoietic stem cell transplantation,allogeneic
hematological malignancies
conditioning regimen
